WHO Pharmaceuticals Newsletter
(No. 2, 2009)
In this issue, we report the suspension of efalizumab in Europe and elsewhere, and the withdrawal of fenfluramine in China. We bring you information on risks and restrictions with some group products (anticonvulsants, antipsychotics, bisphosphonates, SSRIs etc) and advice on some individual drugs in the section on Safety of Medicines. The Feature section includes a short report from the nineteenth meeting of the Global Advisory Committee on Vaccine Safety.